Loading [Contrib]/a11y/accessibility-menu.js
1.
Sutter BA, Thumati P, Thumati RP, Radke J. Meniere’s Disease Patients Treated with Disclusion Time Reduction (DTR): A Retrospective Cohort Study of 86 Patients (Part 1 of 4). Adv Dent Tech. Published online November 3, 2022:10-22.
Download all (9)
  • Figure 1. T-Scan 10 digital occlusal analyzer recording bite force and time synchronized with BioEMG measuring the temporalis (red leads) and masseter muscles (blue-green leads) in real time.
  • Figure 2. Pre-operative bite force data scan with a closure into the intercuspal position and a left lateral excursion. Hyper occlusion on the right posteriors (black arrows), high temporalis activity (blue arrows) and a long disclusion time (green arrows).
  • Figure 3. Same pre-treatment data as in Figure 2, but with the cursor set in the beginning of the excursion. The left temporalis was remarkably hyperactive suggestive of substantial occlusal interferences during the excursion (blue arrow).
  • Figure 4. Post treatment repeat of closure and left lateral excursion as in Figure 1. Reduced forces in the right posterior occlusion (black arrows), reduced muscle activity (blue arrows) and shortened disclusion time (green arrows).
  • Figure 5. Post treatment record with cursor in the excursion and substantial reductions in right posterior occlusal forces, reduced muscle activity (blue arrow) and reduced disclusion time (green arrows).
  • Figure 6. Subjective changes in the intensity, duration, and frequency of vertigo from pre-treatment to 3 months post treatment as indicated by the results of Wilcoxon Signed-Rank test of data from the visual analog scales. All changes were significant (p < 0.00001).
  • Figure 7. Subjective changes in the intensity, duration and frequency of tinnitus from pre-treatment to 3 months post treatment as indicated by results of Wilcoxon Signed-Rank test of data from the visual analog scales. All changes were significant (p < 0.00001).
  • Figure 8. Subjective changes in the intensity, duration and frequency of ear fullness from pre-treatment to 3 months post treatment according to visual analog scale responses. All changes were significant (p < 0.00001).

Abstract

Objective: Diagnosing and effectively treating Meniere’s Disease (MD) remains a significant challenge. There exists no consensus on the etiology in the literature. The purpose of this study was to treat patients diagnosed with MD utilizing the T-Scan Novus and BioEMG III to guide measured occlusal corrections in bite force and timing. The null hypothesis was that occlusal corrections would not significantly improve any MD symptoms.

Methods and Materials: Eighty-six patients diagnosed with MD completed questionnaires that evaluated pain frequency, severity, any functional restrictions and somatization with a PHQ-15 scale, before undergoing Disclusion Time Reduction (DTR) coronoplasty. The questionnaires were repeated 1 month and 3 months post-DTR therapy. Pre and post Disclusion Times (DT) and sEMG temporalis and masseter levels underwent the Student’s t-Test. The MD symptom questionnaire scores were subjected to the Wilcoxon Signed-Rank Test. α = 0.05. Disclusion times and EMG values evaluations were recorded pre and post treatment and subjected to the Student’s paired t-test.

Results: The pre-ICAGD group means of MD symptoms ear fullness, vertigo and tinnitus were significantly reduced in intensity, duration and frequency following DTR (p < 0.00001). Disclusion times and EMG values improved post DTR therapy (p < 0.0001) and correlated to symptom improvement or resolution (p < 0.0001) at 1-month and 3-months post DTR.

Conclusions: In this group of MD subjects, occlusal factors were the major contributor to their MD condition as all occlusally treated subjects reported reductions in symptom frequency, intensity, and duration following DTR therapy. MD may have an overlooked occlusal etiology in long Disclusion Time. DTR should be considered a treatment option in patients diagnosed with MD.

Introduction

Much has been published on Menière’s Disease (MD), which was first identified and characterized by Prosper Menière over 150 years ago.1 Today diagnosing and treating MD among clinicians remains challenging2–7 and as a result MD continues to be a catchall for vertigo of unknown origin. Endolymph Hydrops (EH) remains a histologic finding in most but not all MD cases, while the MD diagnosis remains purely a clinical diagnosis. There is no agreement on the etiology of MD as it relates to endolymphatic hydrops.6,8–12 Current considerations is that EH is a histological sign of the disease rather than a causative etiology.6,9–16 Some research has attempted to induce MD by increasing the endolymph production or limiting its reabsorption through medications. Those models did produce EH but did not produce MD symptoms.17–19 Even if EH does have some influence over vertigo, it does not adequately explain the persistence of tinnitus, ear fullness, or hearing loss progression.

In an attempt to bring clarity to the ENT community a few consensus statements and reviews have been published.6–12 The American Academy of Otolaryngology – Head and Neck Surgery published a clinical practice guideline on MD6 with the stated purpose: “To maximize treatment, it is important to clinically distinguish MD from other independent causes of vertigo that may mimic MD and present with hearing loss, tinnitus and aural fullness.”6 Even though TMD has been known to present with this same presentation of symptoms,20–31 the AAO-HNS fails to make any mention of the similarities in inner ear symptom presentation between TMD and MD anywhere in its 55-page guideline. This is counter intuitive if the aim of their guideline is to distinguish MD from other causes that could mimic MD symptomology.

It is well known that James Costen, an otolaryngologist, read his initial findings of inner ear and sinus symptoms related to disturbed function of the TMJs in 1933 before the Texas Ophthalmological and Otolaryngological Society and was later pubished.32 More recent authors have subsequently labeled his work Costen’s Syndrome, which eventually became known as TMJ Syndrome and currently is labelled as Temporomandibular Disorders (TMD).

In the early 2000’s research spearheaded by Bjorne et al began establishing a link between TMD and MD.22,33–35 Treating TMD patients that were also diagnosed with MD resulted in complete resolution of the MD (and TMD) symptoms or decreased to a level they no longer were life altering for the patient. The symptom resolution was long term as indicated by 3-year and 6-year follow up studies.33,34 Treatments rendered were occlusal adjustments, TMD splint therapy, cervical spine therapy and physical therapy.22,31–35 It is impossible to know if one therapy is responsible for the therapeutic outcome or if it was a result of a synergistic effect of all of the therapies being used in conjunction with each other.

A couple of case studies have shown occlusal adjustments to be highly effective in the treatment of patients that have a diagnosis of Meniere’s Disease.36,37 This study will only use bite revision therapy via DTR in an attempt to bring symptom relief in a cohort of 86 subjects with a diagnosis of MD. DTR has demonstrated effective and long-term symptom resolution in known TMD and Orofacial pain patients.38–47

Objectives

The objective of this cohort study was to perform DTR Therapy on patients with a confirmed diagnosis of MD who presented with long Disclusion Times and/or a bite force imbalance, with high excursive muscle activity levels, all of which could promote MD symptomology. The results of this pilot study will either corroborate or contradict the prior case report’s that observed MD symptom reductions that followed a measured occlusal adjustment therapy.36,37

Methods

Eighty-six patients previously diagnosed by an otolaryngologist (ENT) physician with Meniere’s Disease (MD), were evaluated in two different dental practices that offer specialized Disclusion Time Reduction TMD services. All patients had prior magnetic resonance imaging (MRI), which ruled out auditory neuromas. All the patient’s had tried various treatments from dietary restrictions such as avoidance of salt and caffeine to inner ear gentamycin and stem cell injections. None of these treatment options brought about relief for any length of time. While patients were not selected at random, they were random in the sense all were consecutive patients based on their presentation to each of the two dental offices. One general dentistry office located in Eugene, OR where 32 consecutive patients diagnosed with MD were seen successively in the sense whoever walked in and met the inclusion criteria were evaluated and treated. The second dental office is located within the RajaRajeshwari Dental College, Dept of Orofacial Pain under Rajiv Gandhi University of Health Sciences in Bengaluru India. The Dept of Ear Nose and Throat at RajaRajeshwari Medical College was contacted to seek out patients that met the inclusion criteria sent to the second dental office to be evaluated and treated. An IRB approval was requested and obtained for a retrospective cohort study #BIRB/99Z/2022.

The Inclusion criteria were:

  • A MD diagnosis from an otolaryngologist with MRI that definitively ruled out an auditory neuroma

  • The existence of ongoing MD symptomatic episodes

  • 28 teeth with symmetrically missing teeth (if one molar was missing on the left side, then one had to be missing on the right side)

  • Near normal occlusal relations with molars and premolars in contact during the right and left excursions

  • Angles Class I and Class III occlusal relations, with guiding anterior teeth that were either in contact, or near to contact

  • Patients that had been previously treated for MD but did not receive symptom resolution

  • Patients 18 years of age or older

The Exclusion criteria were:

  • Severe Class II malocclusions and anterior open bite where anterior guidance contact could not be achieved

  • A previous history of TMJ trauma

  • The presence of unstable Temporomandibular Joint internal derangements verified by CBCT and/or Joint Vibration Analysis (JVA).

  • Patients that had been previously treated with MD therapy that received symptom resolution

  • Patients who had undergone prior TMD therapy, including prior occlusal adjustment treatment.

  • Patients younger than 18 years of age

Informed consent was obtained for each patient undergoing the DTR coronoplasty, and for collecting MD symptom severity, frequency and duration data from questionnaires. Oral health histories were also obtained where the whole participant group reported experiencing MD symptoms. All the group reported fullness in the ear, tinnitus, vertigo (including drop attacks) and hearing loss in at least one ear. Surprisingly the group also reported many TMD symptoms with moderate to severe frequencies and intensities. The TMD symptoms seemed to be randomly distributed and no correlation could be made with any one symptom to the MD symptoms.

Every participant underwent a pre-ICAGD right and left excursive Disclusion Time/muscle hyperactivity evaluation with the synchronized T-Scan 10/BioEMG III technologies (Tekscan Inc., S. Boston, MA USA; Bioresearch Assoc., Inc. Milwaukee, WI, USA). See Figure 1.

Figure 1
Figure 1.T-Scan 10 digital occlusal analyzer recording bite force and time synchronized with BioEMG measuring the temporalis (red leads) and masseter muscles (blue-green leads) in real time.

Subjects closed firmly into their Maximum Intercuspation Position (MIP) Figure 2, clenched their teeth together for 1-3 seconds, and then completed a single-movement excursion Figure 3 (right or left) until only their anterior teeth were in contact. They repeated the recording so that 2 different recordings were made, one to the right and one to the left. This allowed accurate EMG and disclusion times to be recorded prior to the therapy.

Figure 2 illustrates a closure into the intercuspal position, followed by an attempted left lateral excursion. The patient reported the affected ear was the right one. The right posterior quadrant has the greatest amount of closure force which is 43% of total bite force (black arrows). In general, the EMG recordings for the Temporalis and Masseter should roughly be equal in MIP of healthy subjects. What is observed here is the temporalis muscles are firing 5 times higher in amplitude (blue arrows).

Figure 2
Figure 2.Pre-operative bite force data scan with a closure into the intercuspal position and a left lateral excursion. Hyper occlusion on the right posteriors (black arrows), high temporalis activity (blue arrows) and a long disclusion time (green arrows).

Figure 3 reproduces the same pre therapy scan in Figure 1 but shows the activity early during the left excursive direction and that the patient is locked in on the right side (black arrow) tooth #2. The muscles were hyperactive throughout the scan but peak at 437.9 microvolts during the movement (blue arrow). The pre-op Disclusion time is 0.82 seconds (green arrows). There is no anterior guidance which creates prolonged disclusion over 0.50 seconds and this is time is being reduced with the coronoplasty (green arrows).

Figure 3
Figure 3.Same pre-treatment data as in Figure 2, but with the cursor set in the beginning of the excursion. The left temporalis was remarkably hyperactive suggestive of substantial occlusal interferences during the excursion (blue arrow).

Description of the DTR Therapy

The therapy is described elsewhere in detail.38,48 Briefly, teeth were dried on one side of the mouth (top and bottom), then the subjects closed into their Maximum Intercuspal Position (MIP) with 21-micron thick articulating paper (Parkell, Englewood, NY, USA) between the teeth. Then the subject moves into a right excursive all the way out to the tip of the canine, then back into MIP, then this excursive movement is repeated to the left and back into MIP. The pre-treatment recordings then guided the authors to the appropriate areas of occlusal surfaces that necessitate corrective adjustments. The posterior working and non-working lateral interferences are completely removed and centric stop contacts are revised from broad contacts into small pinpoint contacts located on supporting cusps, marginal ridges and central fossae. This is then repeated on the opposite side.

DTR therapy was considered complete when:

  1. All lateral posterior excursive interferences are removed

  2. Disclusion times had measurably been reduced to < 0.5 seconds in both directions

  3. Habitual closure contacts were located solely on cusp tips, fossae and on marginal ridges

  4. T-Scan revealed that patient self-closure into MIP achieved bilateral simultaneous force rise

Post therapy recordings were taken in the same fashion as the pre therapy recordings to confirm disclusion times were correct. Patients were seen at day 1, at one month and 3 months to refine the above procedure. This allowed muscles to heal after the occlusal corrections. At each of the 3 visits, subjects filled out new questionnaires regard symptom frequency, duration, and intensity. All subjects’ self-assessment data were subjected to the Wilcoxon Signed-Rank Test. Disclusion Time values and EMG levels pre and post therapy were subjected to Student’s paired t-test (Alpha = 0.05). This concluded both the treatment and data collection stages of the study.

Figure 4 is the same patient as in Figure 2 post treatment for comparison following the DTR therapy. The force outlier on tooth #2 was corrected from 19.1% to 9.3% (black arrows). Post therapy the hyperactive muscles have decreased from 366 R /367 L microvolts to 60 R/60 L microvolts (blue arrows). The Disclusion Time was reduced from 0.82 seconds in Figure 2 to 0.29 seconds (green arrows).

Figure 4
Figure 4.Post treatment repeat of closure and left lateral excursion as in Figure 1. Reduced forces in the right posterior occlusion (black arrows), reduced muscle activity (blue arrows) and shortened disclusion time (green arrows).

Figure 5 is a post operative scan compared to pre-treatment scan in in the same manner as Figure 3 with the cursor moved into the part of the scan that reveals left movement. Canine guidance took over as the teeth came apart and the non-working interference on tooth #2 was also corrected (black arrow). Note that EMG data from Figure 3 was 437.9 microvolts which dropped to 7.9 microvolts post DTR (blue arrow) in Figure 5.

Figure 5
Figure 5.Post treatment record with cursor in the excursion and substantial reductions in right posterior occlusal forces, reduced muscle activity (blue arrow) and reduced disclusion time (green arrows).

Results

The goal of objectively reducing the subjects’ Disclusion Times was achieved as shown in Table 1. These were statistically significant reductions (p < 0.00001) for every subject in the MD cohort out to six months. There were statistically significant reductions in the group muscle activity level EMG means of all 4 muscles (right and left temporalis anterior & right and left masseter muscles) from pre to post therapy that coincided with shortening the disclusion times. See Table 2.

Table 1.Changes in Disclusion Time pre to post treatment. Analysis by Student’s Paired t tests.
Left Disclusion time Pre-Tx (seconds) Right Disclusion time Pre-Tx (seconds) Left Disclusion 6 mos. Post-Tx (seconds) Right Disclusion 6 mos. Post-Tx (seconds)
Means 2.258 2.265 0.283 0.295
Standard Deviations 1.258 1.344 0.078 0.080
Student's Paired t tests - p < ^-------------------0.00001-----------------^
^------------------0.00001------------------^
Table 2.Changes in EMG muscle activity pre to post treatment. Analysis by Student’s Paired t tests.
EMG Activity Pre to Post Treatment Mean muscle levels at "C" (microvolts) Mean muscle levels at "D" (microvolts)
Pre-Treatment Means 61.3 31.2
Pre-Treatment SDs 60.10 52.38
Student's Paired t test - p < 0.3143 0.00001
6 Months Post Treatment Means 60.2 12.3
6 Months Post Treatment Sds 44.27 12.80

Tx = Treatment, SD = Standard Deviation

VAS scores were averaged for the 86 subjects for intensity, duration and frequency of vertigo, tinnitus and ear fullness at day 1 pretreatment, at one month and at three months post therapy. See Figures 68. Hearing loss improvement could not be quantified or tabulated but many subjects stated that their hearing had subjectively improved. Audiometric examination was not consistently accomplished as part of the diagnostic process for most of the subjects and no follow-up test was possible because the “gold standard hearing test” was not readily available for the two dental offices.

Some researchers caution that the diagnosis of MD can be rendered in the absence of all of the symptoms and hearing loss is not needed to render the diagnosis.16 This would create many false positive diagnoses if 25% of the symptoms could be omitted from the clinical assessment for MD.

The 3 clinical symptoms, the only ones that could be subjectively quantified by the patients (VAS), were vertigo, tinnitus and ear fullness. The subjective levels of vertigo were dramatically reduced significantly (p < 0.00001) at one month after DTR treatment and continued to reduce at three months post-DTR (P < 0.00001). See Figure 6.

Figure 6
Figure 6.Subjective changes in the intensity, duration, and frequency of vertigo from pre-treatment to 3 months post treatment as indicated by the results of Wilcoxon Signed-Rank test of data from the visual analog scales. All changes were significant (p < 0.00001).

Equally dramatic significant reductions in Tinnitus were observed at one month post treatment and again at three months post treatment. See Figure 7.

Figure 7
Figure 7.Subjective changes in the intensity, duration and frequency of tinnitus from pre-treatment to 3 months post treatment as indicated by results of Wilcoxon Signed-Rank test of data from the visual analog scales. All changes were significant (p < 0.00001).

Significant reductions in the subjective sensation of ear fullness were observed at one month post treatment and again at three months post treatment. See Figure 8.

Figure 8
Figure 8.Subjective changes in the intensity, duration and frequency of ear fullness from pre-treatment to 3 months post treatment according to visual analog scale responses. All changes were significant (p < 0.00001).

Discussion

The findings of this 86-cohort study corroborated the prior MD clinical reports36,37 in that shortening the Disclusion Time with ICAGD in these 86 subjects, resolved many MD symptoms within a short period of time, that lasted through the 3-months period of observation."

In the previous two DTR/Meniere’s case studies36,37 it was hypothesized that there are only four possible explanations for the observations made in the treatment of MD patients by DTR:

  • MD is a real subset of TMDs.

  • MD was a misdiagnosis, and the patient really suffered from a TMD variant.

  • The patient had two different active disease states occurring concurrently, that resolved simultaneously following DTR therapy.

  • There exists one specific type of MD that involves dental occlusion.

Given the statistical distribution of these results, the simplest explanation is patients suffering from TMD symptoms were erroneously diagnosed with MD. The recognized etiology of MD cannot contain the actual causal factor of this disease process. Otherwise, the authors would have observed a bimodal distribution of subjects where positive outcomes were observed for participants with an underlying TMD diagnosis while a separate peak for subjects that gained no benefit from the treatment for participants with a true MD diagnosis. Even if EH is the cause of vertigo, it does not adequately explain tinnitus, ear fullness and hearing loss. The subjects in this study reported improvements in ear fullness, vertigo, tinnitus, and hearing loss, which are the clinical symptoms used in the diagnosed of MD.

The least responsive subject’s intensity of tinnitus dropped from 10 to 2, the frequency of tinnitus from 2 to 1, but the duration of tinnitus remained at 5, unchanged at 3 months post DTR. However, that subject’s vertigo reduced in intensity from 9 to zero, in duration from 5 to zero and in frequency from 5 to zero. The ear fullness intensity reduced from 7 to zero, the duration from 4 to zero and the frequency from 3 to 1. In total even the least responsive subject received a significant reduction in overall symptoms. It would not be credible to claim that any of these 86 subjects diagnosed with MD did not respond positively to occlusal adjustment via DTR. Unless there is another variant of MD that was somehow not included within this sample of 86 MD patients, it would appear that MD is very responsive to DTR treatment. Perhaps the reason the disease is so enigmatic is because medicine and dentistry have been looking under the wrong stones for answers.

There exists a handful of treatments for MD with inconsistent outcomes most only accomplishing temporary relief.49–54 Current treatment options that are the most efficacious are more invasive and pose a greater risk for hearing loss.55 To be clear, these authors are not advocating just any TMD/TMJ therapy as a first step before inner ear injection or surgeries are attempted. The DTR therapy rendered in this study contains very strict protocols with specific biometric endpoints that have been shown to bring substantial relief to patients diagnosed with MD.

The literature is incorporating more symptoms that are known TMD symptoms into the MD landscape instead of completing a comparison in symptoms between the diagnoses. It must be stated it has already been reported that 90% of MD patients did have neck pain and or headaches. This included tightness in the neck and or asymmetry of the shoulders.56 Postural problems with a component of myofascial problems “are the real culprit which lead to a series of events with end organ affection at inner ear level causing vestibular symptoms.”56 This phenomena has been observed in other parts of the body where one hypercontracted muscle sets off a cascade of other muscles to behave in the same manner making up a chain of tight muscles.57–59 Also some researchers have proposed an association between migraine and MD, where MD patients have migraines 4 time more often than controls.60 Some researchers have reported observing MD in patients as young as 6 years old.3,61–64 “Chronic recurrent headaches occur in approximately 40% of children at age of seven, increasing to 75% by the age of fifteen years.”65 These two disease processes and the age of possible onset is interesting because dentistry observes that the first adult molar erupts around age 6 and the second adult molar around the age of 12. Furthermore, some have found associations involving MD and vestibular migraines,66 both having headaches and migraines. Interestingly, these researchers stated “neither the decision tree analysis nor the logistical regression analysis could reliably discriminate VM from MD.”66 The authors suggested MD and VM may share similar etiology.66

This study supports the concept that rather than being separate entities, MD and malocclusion are one disease process with two different diagnoses depending on which professional confirms the diagnosis: otolaryngologist or dentist. Insight and treatment into the actual etiology of MD can prevent symptom reappearance as well as progression and worsening of the disease process. The authors propose the American Academy of Otolaryngology –Head and Neck Surgery adopt a symptoms screening protocol to include Menière’s Disease within the category of Temporomandibular Disorders (TMD) in the future to avoid needless treatments and wasted resources. In the appendix the authors have included a symptoms sheet that might be a good starting point. The symptoms included here are also known as TMD symptoms.

Limitations

Despite the very small p values suggesting a high statistical significance in the reduction of MD symptoms there were no control subjects. This should be done in the future with some of the subjects randomly assigned to a control group and the remainder assigned to the treatment group. This study attempted to determine a measured effect of DTR occlusal adjustments using the subjects as their own controls. To compensate for this limitation many self-report questionnaires were used to determine the improvements in MD symptoms from pre to post DTR treatment.

Conclusion

Eighty-six subjects with a confirmed diagnosis of Meniere’s Disease experienced reductions in frequency, duration and intensity of their MD symptoms following reductions in Disclusion Time and muscle activity via DTR through computer guided coronoplasty. Although occlusion has been overlooked in most of the medical and dental literature as a possible etiology of MD, the results of this study point to malocclusion, specifically bite force and bite timing, as the etiology for the symptoms in this group of subjects diagnosed with MD.


Note

This data set will be used in four different articles. Part 1 evaluates patients diagnosed with MD and how DTR improves the clinical symptoms that are used in the diagnosis of MD. Part 2 will review EMG and EGN data of Masticatory function. Part 3 will review Joint Vibration Analysis changes and part 4 will address TMD vs MD and Somatic Symptom Disorders from PHQ-15 scores and functional scores, all to shed new light on MD etiology.

Statement of Possible Conflicts

Drs. Ben Sutter, Prafulla Thumati, and Roshan Thumati claim no conflict of interest. John Radke is the Chairman of the Board of BioResearch Associates, Inc. the manufacturer of the BioEMG III. He receives no commission or other monetary incentive from sales of the T-Scan 10 or the BioEMG III.

Statement of Funding

No funding from any source was provided to complete this study.

Accepted: November 22, 2022 CDT

References

1.
Méniere “Sur une forme de surdité grave dépendant d’une lésion de l’oreille interne” (On a form of severe deafness dependent on a lesion of the inner ear). Bulletin de l’Académie impériale de médecine. 1861;26:26241.
Google Scholar
2.
Perez-Carpena P, Lopez-Escamez JA. Current Understanding and Clinical Management of Meniere’s Disease: A Systematic Review. Semin Neurol. 2020;40(1):138-150. doi:10.1055/​s-0039-3402065
Google Scholar
3.
Mancini F, Catalani M, Carru M, Monti B. History of Meniere’s disease and its clinical presentation. Otolaryngol Clin North Am. 2002;35(3):565-580. doi:10.1016/​s0030-6665(02)00017-8
Google Scholar
4.
Oberman BS, Patel VA, Cureoglu S, Isildak H. The aetiopathologies of  Ménière’s disease: a contemporary review. Acta Otorhinolaryngol Ital. 2017;37(4):250-263. doi:10.14639/​0392-100x-793
Google ScholarPubMed CentralPubMed
5.
Harris JP, Nguyen QT. Meniere’s disease: 150 years and still elusive. Otolaryngol Clin North Am. 2010;43(5):xiii-xiv. doi:10.1016/​j.otc.2010.05.011
Google Scholar
6.
Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Ménière’s Disease. Otolaryngol Head Neck Surg. 2020;162(S2):S1-S55. doi:10.1177/​0194599820909438
Google Scholar
7.
Hegemann SCA. Menière’s disease caused by CGRP - A new hypothesis explaining etiology and pathophysiology. Redirecting Menière’s syndrome to Menière’s disease. J Vestib Res. 2021;31(4):311-314. doi:10.3233/​ves-200716
Google Scholar
8.
Gürkov R, Pyykö I, Zou J, Kentala E. What is Menière’s disease? A contemporary re-evaluation of endolymphatic hydrops. J Neurol. 2016;263(S1):71-81. doi:10.1007/​s00415-015-7930-1
Google ScholarPubMed CentralPubMed
9.
Christopher LH, Wilkinson EP. Meniere’s disease: Medical management, rationale for vestibular preservation and suggested protocol in medical failure. Am J Otolaryngol. 2021;42(1):102817. doi:10.1016/​j.amjoto.2020.102817
Google Scholar
10.
Merchant SN, Adams JC, Nadol JBJr. Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol. 2005;26(1):74-81. doi:10.1097/​00129492-200501000-00013
Google Scholar
11.
Morgan DH. Tinnitus of TMJ Origin: A Preliminary Report. Cranio. 1992;10(2):124-129. doi:10.1080/​08869634.1992.11677900
Google Scholar
12.
Iwasaki S, Shojaku H, Murofushi T, et al. Diagnostic and therapeutic strategies for Meniere’s disease of the Japan Society for Equilibrium Research. Auris Nasus Larynx. 2021;48(1):15-22. doi:10.1016/​j.anl.2020.10.009
Google Scholar
13.
Foster CA, Breeze RE. Endolymphatic hydrops in Ménière’s disease: cause, consequence, or epiphenomenon? Otol Neurotol. 2013;34(7):1210-1214. doi:10.1097/​mao.0b013e31829e83df
Google Scholar
14.
Cureoglu S, da Costa Monsanto R, Paparella MM. Histopathology of Meniere’s Disease. Oper Tech Otolayngol Head Neck Surg. 2016;27(4):194-204. doi:10.1016/​j.otot.2016.10.003
Google ScholarPubMed CentralPubMed
15.
Harris JP, Nguyen QT. Meniere’s disease: 150 years and still elusive. Otolaryngol Clin North Am. 2010;43(5):xiii-xiv. doi:10.1016/​j.otc.2010.05.011
Google Scholar
16.
Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Menière’s disease. J Vestib Res. 2015;25(1):1-7. doi:10.3233/​ves-150549
Google Scholar
17.
Takumida M, Akagi N, Anniko M. A new animal model for Ménière’s disease. Acta Otolaryngol. 2008;128(3):263-271. doi:10.1080/​00016480701497436
Google Scholar
18.
Kumagami H, Loewenheim H, Beitz E, et al. The effect of anti-diuretic hormone on the endolymphatic sac of the inner ear. Pflugers Arch. 1998;436(6):970-975. doi:10.1007/​s004240050731
Google Scholar
19.
Feldman AM, Brusilow SW. Effects of cholera toxin on cochlear endolymph production: model for endolymphatic hydrops. Proc Natl Acad Sci USA. 1976;73(5):1761-1764. doi:10.1073/​pnas.73.5.1761
Google ScholarPubMed CentralPubMed
20.
Cooper BC, Kleinberg I. Examination of a Large Patient Population for the Presence of Symptoms and Signs of Temporomandibular Disorders. Cranio. 2007;25(2):114-126. doi:10.1179/​crn.2007.018
Google Scholar
21.
Peroz I. Dysfunctions of the stomatognathic system in tinnitus patients compared to controls. HNO. 2003;51(7):544-549.
Google Scholar
22.
Bjorne A, Agerberg G. Craniomandibular disorders in patients with Menière’s disease: a controlled study. J Orofac Pain. 1996;10(1):28-37.
Google Scholar
23.
Björne A. Assessment of temporomandibular and cervical spine disorders in tinnitus patients. Prog Brain Res. 2007;166:215-219. doi:10.1016/​s0079-6123(07)66019-1
Google Scholar
24.
Gelb H, Gelb ML, Wagner ML. The relationship of tinnitus to craniocervical mandibular disorders. Cranio. 1997;15(2):136-143. doi:10.1080/​08869634.1997.11746004
Google Scholar
25.
Ferendiuk E, Zajdel K, Pihut M. Incidence of otolaryngological symptoms in patients with temporomandibular joint dysfunctions. Biomed Res Int. 2014;2014:824684. doi:10.1155/​2014/​824684
Google ScholarPubMed CentralPubMed
26.
Wright EF, Syms CA III, Bifano SL. Tinnitus, dizziness, and nonotologic otalgia improvement through temporomandibular disorder therapy. Mil Med. 2000;165(10):733-736. doi:10.1093/​milmed/​165.10.733
Google Scholar
27.
Wright EF, Bifano SL. The Relationship between Tinnitus and Temporomandibular Disorder (TMD) Therapy. Int Tinnitus J. 1997;3(1):55-61.
Google Scholar
28.
Di Berardino F, Filipponi E, Schiappadori M, Forti S, Zanetti D, Cesarani A. The occlusal imaging and analysis system by T-scan III in tinnitus patients. Biomed J. 2016;39(2):139-144. doi:10.1016/​j.bj.2016.04.001
Google ScholarPubMed CentralPubMed
29.
Kusdra PM, Stechman-Neto J, de Leão BLC, Martins PFA, de Lacerda ABM, Zeigelboim BS. Relationship between Otological Symptoms and TMD. Int Tinnitus J. 2018;22(1):30-34. doi:10.5935/​0946-5448.20180005
Google Scholar
30.
Ramirez Aristeguieta LM, Sandoval Ortiz GP, Ballesteros LE. Theories on otic symptoms in temporomandibular disorders: past and present. Int J Morphol. 2005;23(2):141-156. doi:10.4067/​s0717-95022005000200009
Google Scholar
31.
Stechman-Neto J, Porporatti AL, Porto de Toledo I, et al. Effect of temporomandibular disorder therapy on otologic signs and symptoms: a systematic review. J Oral Rehabil. 2016;43(6):468-479. doi:10.1111/​joor.12380
Google Scholar
32.
Costen JB. A syndrome of ear and sinus symptoms dependent upon disturbed function of the temporomandibular joint. Ann Otol Rhinol Laryngol. 1997;106(10):805-819. doi:10.1177/​000348949710601002
Google Scholar
33.
Bjorne A, Agerberg G. Symptom relief after treatment of temporomandibular and cervical spine disorders in patients with Meniere’s disease: a three-year follow-up. Cranio. 2003;21(1):50-60. doi:10.1080/​08869634.2003.11746232
Google Scholar
34.
Bjorne A, Agerberg G. Reduction in sick leave and costs to society of patients with Meniere’s disease after treatment of temporomandibular and cervical spine disorders: a controlled six-year cost-benefit study. Cranio. 2003;21(2):136-143. doi:10.1080/​08869634.2003.11746242
Google Scholar
35.
Bjorne A, Berven A, Agerberg G. Cervical signs and symptoms in patients with Meniere’s disease: a controlled study. Cranio. 1998;16(3):194-202. doi:10.1080/​08869634.1998.11746057
Google Scholar
36.
Sutter BA. Two Case Reports of Meniere’s Disease That Responded to Computer-guided Occlusal Therapy. The Application of the Principles of Neuromuscular Dentistry to Clinical Practice. Anthology Vol XI, The International College of Cranio-Mandibular Orthopedics. 2016;11:89-98.
Google Scholar
37.
Sutter BA. Complex Medical Diagnoses with an Underlying Dental Etiology; Case Reviews. In: Kerstein RB, ed. Handbook of Research on Clinical Applications of Computerized Occlusal Analysis in Dental Medicine. IGI Global; 2019:1243-1315.
Google Scholar
38.
Kerstein RB. Disclusion Time reduction therapy with immediate complete anterior guidance development: the technique. Quintessence Int. 1992;23(11):735-747.
Google Scholar
39.
Kerstein RB, Radke J. Masseter and temporalis excursive hyperactivity decreased by measured anterior guidance development. Cranio. 2012;30(4):243-254. doi:10.1179/​crn.2012.038
Google Scholar
40.
Kerstein RB, Radke J. Average Chewing Pattern improvements following Disclusion Time Reduction. Cranio. 2017;35(3):135-151. doi:10.1080/​08869634.2016.1190526
Google Scholar
41.
Kerstein RB, Chapman R, Klein M. A comparison of ICAGD (Immediate Complete Anterior Guidance Development) to “mock ICAGD” for symptom reductions in chronic myofascial pain dysfunction patients. Cranio. 1997;15(1):21-37. doi:10.1080/​08869634.1997.11745990
Google Scholar
42.
Thumati P, Sutter BA, Kerstein RB, Yiannios N, Radke J. Beck Depression Inventory changes in muscular TMD subjects after measured occlusal treatment. ADT&T. 2018;1(1):1-13.
Google Scholar
43.
Kerstein RB, Wright N. Electromyographic and computer analysis of patients suffering from chronic myofascial pain-dysfunction syndrome: before and after treatment with immediate complete anterior guidance development. J Prosthet Dent. 1991;66(5):677-686.
Google Scholar
44.
Thumati P, Manwani R, Mahantshetty M. The effect of reduced Disclusion Time in the treatment of myofascial pain dysfunction syndrome using immediate complete anterior guidance development protocol monitored by digital analysis of occlusion. Cranio. 2014;32(4):289-299. doi:10.1179/​2151090314y.0000000004
Google Scholar
45.
Thumati P, Thumati RP. The effect of disocclusion time-reduction therapy to treat chronic myofascial pain: A single group interventional study with 3-year follow-up of 100 cases. J Indian Prosthodont Soc. 2016;16(3):234-241. doi:10.4103/​0972-4052.176529
Google ScholarPubMed CentralPubMed
46.
Yiannios N, Kerstein RB, Radke J. Treatment of frictional dental hypersensitivity (FDH) with computer-guided occlusal adjustments. Cranio. 2017;35(6):347-357. doi:10.1080/​08869634.2016.1251692
Google Scholar
47.
Sutter B, Teragawa S, Radke J. Trigeminal Neuralgia Patients Treated with Disclusion Time Reduction (DTR): A Retrospective Cohort Study. ADT&T. 2020;2(2):90-105.
Google Scholar
48.
Kerstein RB. A comparison of traditional occlusal equilibration and immediate complete anterior guidance development. Cranio. 1993;11(2):126-140. doi:10.1080/​08869634.1993.11677954
Google Scholar
49.
Ballard DP, Sukato DC, Timashpolsky A, Babu SC, Rosenfeld RM, Hanson M. Quality-of-Life Outcomes following Surgical Treatment of Ménière’s Disease: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2019;160(2):232-238. doi:10.1177/​0194599818803612
Google Scholar
50.
Guan Y, Chari DA, Liu YH, Rauch SD. Efficacy and Durability of Intratympanic Gentamicin Treatment for Meniere’s Disease. Front Neurol. 2021;12:765208. doi:10.3389/​fneur.2021.765208
Google ScholarPubMed CentralPubMed
51.
Molnár A, Maihoub S, Tamás L, Szirmai Á. Conservative Treatment Possibilities of Ménière Disease, Involving Vertigo Diaries. Ear Nose Throat J. 2021;100(7):536-542. doi:10.1177/​0145561319881838
Google Scholar
52.
Durland WF Jr, Pyle GM, Connor NP. Endolymphatic sac decompression as a treatment for Meniere’s disease. Laryngoscope. 2005;115(8):1454-1457. doi:10.1097/​01.mlg.0000171017.41592.d0
Google Scholar
53.
Gates GA. Treatment of Meniere’s disease with the low-pressure pulse generator (Meniett device). Expert Rev Med Devices. 2005;2(5):533-537. doi:10.1586/​17434440.2.5.533
Google Scholar
54.
Shea JJ Jr. The classification and treatment of Menière’s disease. Acta Otorhinolaryngol Belg. 1993;47(3):303-310.
Google Scholar
55.
Flores García M, Llata Segura C, Cisneros Lesser J, Pane Pianese C. Endolymphatic Sac Surgery for Ménière’s Disease – Current Opinion and Literature Review. Int Arch Otorhinolaryngol. 2017;21(2):179-183. doi:10.1055/​s-0037-1599276
Google ScholarPubMed CentralPubMed
56.
Jain S, Jungade S, Ranjan A, et al. Revisiting “Meniere’s Disease” as “Cervicogenic Endolymphatic Hydrops” and Other Vestibular and Cervicogenic Vertigo as “Spectrum of Same Disease”: A Novel Concept. Indian J Otolaryngol Head Neck Surg. 2021;73(2):174-179. doi:10.1007/​s12070-020-01974-y
Google ScholarPubMed CentralPubMed
57.
Busquet L. Les chaines physiologiques: Tome 5, Traitement du crane. 5th (in French). ISBN-10
Google Scholar
58.
Sutter BA, Girouard P. Posture Stability and Forward Head Posture Before and After Disclusion Time Reduction (DTR). A Five-Year Cohort Study. ADT&T. 2021;3(2):23-35.
Google Scholar
59.
Girouard P, Stark PC, Sutter BA. Treatment of Temporomandibular Joint Disorders with an Oral Orthotic Provides Postural Stabilization: A Retrospective Cohort Analysis. Adv Dent Tech. 2020;3(1):63-72.
Google Scholar
60.
Sarna B, Abouzari M, Lin HW, Djalilian HR. A hypothetical proposal for association between migraine and Meniere’s disease. Med Hypotheses. 2020;134:109430. doi:10.1016/​j.mehy.2019.109430
Google ScholarPubMed CentralPubMed
61.
Aust G, Novotný M. Ménière’s disease and various types of vertigo in children. Int Tinnitus J. 2005;11(1):66-68.
Google Scholar
62.
Wang C, Wu CH, Cheng PW, Young YH. Pediatric Meniere’s disease. Int J Pediatr Otorhinolaryngol. 2018;105:16-19. doi:10.1016/​j.ijporl.2017.11.029
Google Scholar
63.
Choung YH, Park K, Kim CH, Kim HJ, Kim K. Rare cases of Ménière’s disease in children. J Laryngol Otol. 2006;120(4):343-352. doi:10.1017/​s0022215106000569
Google Scholar
64.
Rodgers GK, Telisehi FF. Meniere’s disease in children. Otolaryngol Clin North Am. 1997;30(6):1101-1104. doi:10.1016/​s0030-6665(20)30151-1
Google Scholar
65.
Shah UH, Kalra V. Pediatric migraine. Int J Pediatr. 2009;2009:424192. doi:10.1155/​2009/​424192
Google ScholarPubMed CentralPubMed
66.
Pyykkö I, Manchaiah V, Färkkilä M, Kentala E, Zou J. Association between Ménière’s disease and vestibular migraine. Auris Nasus Larynx. 2019;46(5):724-733. doi:10.1016/​j.anl.2019.02.002
Google Scholar

Appendix 1